Literature DB >> 8561688

Interferon-induced sudden hearing loss.

Y Kanda1, K Shigeno, H Matsuo, M Yano, N Yamada, H Kumagami.   

Abstract

With the increasing long-term use of interferon (IFN), several new adverse effects have been recognized. Very little attention, however, has been paid to auditory acuity. We encountered 3 cases of sudden hearing loss associated with IFN. We then conducted a prospective study to assess the auditory function of 73 patients receiving IFN. Auditory disability (tinnitus and/or hearing loss) occurred in 32 patients (43.8%) during IFN therapy, among which audiometry documented sensorineural hearing loss in 27 cases (36.9%); 17 (48.6%) of the 35 patients receiving IFN-beta had auditory disability, including hearing loss in 13 cases (37.1%), and 15 (39.5%) of 38 patients receiving IFN-alpha suffered from auditory disability. There was not much difference between the influences of IFN-alpha and -beta. Auditory disability frequently developed in the later stages of treatment, and most patients recovered 7-14 days after the discontinuation of IFN. The results demonstrate that sudden hearing loss can occur as a side effect of treatment with IFN. This may reveal the association between autoimmunity and sudden hearing loss.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8561688     DOI: 10.3109/00206099509071903

Source DB:  PubMed          Journal:  Audiology        ISSN: 0020-6091


  8 in total

1.  Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.

Authors:  Savita Jain; Vandana Midha; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2011-09

2.  Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy.

Authors:  Victor-K Wong; Cindy Cheong-Lee; Jo-Ann-E Ford; Eric-M Yoshida
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

3.  Effect of interferon treatment on hearing of patients with chronic hepatitis C.

Authors:  Abdulrahman Hagr; Dima Jamjoom; Faisal M Sanai; Waleed Al Hamoudi; Ayman A Abdo; Ahmed Al-Arfaj
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

4.  Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.

Authors:  Hela Elloumi; Fatma Houissa; Najet-Bel Hadj; Dalila Gargouri; Malika Romani; Jamel Kharrat; Abdeljabbar Ghorbel
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

5.  A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone.

Authors:  Vu Le; Ted Bader; Javid Fazili
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

Review 6.  A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.

Authors:  Christine Little; Maura K Cosetti
Journal:  Laryngoscope       Date:  2021-01-27       Impact factor: 2.970

7.  INF- α and ototoxicity.

Authors:  Mohammad Reza Sharifian; Shima Kamandi; Hamid Reza Sima; Mohammad Ali Zaringhalam; Mehdi Bakhshaee
Journal:  Biomed Res Int       Date:  2013-07-25       Impact factor: 3.411

8.  Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir.

Authors:  Elshahat Ibrahem Ismail; Ashraf Elsayed Morgan; Raghda Elsayed Farag
Journal:  J Otol       Date:  2017-12-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.